EP0560929A4 - - Google Patents

Info

Publication number
EP0560929A4
EP0560929A4 EP19920902709 EP92902709A EP0560929A4 EP 0560929 A4 EP0560929 A4 EP 0560929A4 EP 19920902709 EP19920902709 EP 19920902709 EP 92902709 A EP92902709 A EP 92902709A EP 0560929 A4 EP0560929 A4 EP 0560929A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920902709
Other versions
EP0560929A1 (en
Inventor
Henry C. Marsh, Jr.
Patrick C. Kung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Cell Sciences Inc
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of EP0560929A1 publication Critical patent/EP0560929A1/en
Publication of EP0560929A4 publication Critical patent/EP0560929A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
EP92902709A 1990-12-06 1991-12-06 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity Withdrawn EP0560929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62387890A 1990-12-06 1990-12-06
US623878 1990-12-06

Publications (2)

Publication Number Publication Date
EP0560929A1 EP0560929A1 (en) 1993-09-22
EP0560929A4 true EP0560929A4 (xx) 1994-08-31

Family

ID=24499761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92902709A Withdrawn EP0560929A1 (en) 1990-12-06 1991-12-06 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Country Status (6)

Country Link
EP (1) EP0560929A1 (xx)
JP (1) JPH06503344A (xx)
KR (1) KR930703011A (xx)
AU (1) AU9149791A (xx)
CA (1) CA2097825A1 (xx)
WO (1) WO1992010205A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5366986A (en) * 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
GB9301289D0 (en) * 1993-01-22 1993-03-17 Smithkline Beecham Plc Novel composition
CA2155933C (en) * 1993-02-12 2000-04-04 James L. Levin Pulmonary administration of scr1 and other complement inhibitory proteins
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
DK1755674T3 (en) 2004-05-14 2015-02-09 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
PL1988882T3 (pl) 2006-03-02 2015-04-30 Alexion Pharma Inc Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
PL2061810T3 (pl) 2006-09-05 2015-05-29 Alexion Pharma Inc Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009220A1 (en) * 1988-04-01 1989-10-05 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)
WO1991005047A1 (en) * 1989-09-26 1991-04-18 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212051A (en) * 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
ES2054641T3 (es) * 1987-09-30 1994-08-16 Mucos Emulsions Gmbh Utilizacion de enzimas catabolicas para la preparacion de un medicamento destinado a combatir la inmunodeficiencia adquirida (sida) y sus etapas previas (sla y crs).
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009220A1 (en) * 1988-04-01 1989-10-05 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)
WO1991005047A1 (en) * 1989-09-26 1991-04-18 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D.T. FEARON: "Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors.", CLIN. EXP. IMMUNOL., vol. 86, no. SUP1, October 1991 (1991-10-01), pages 43 - 46 *
H.F. WEISMAN: "Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.", SCIENCE, vol. 249, no. 4965, 1990, pages 146 - 151 *
J IMMUNOL, (1979 JUN) 122 (6) 2418-23 *
See also references of WO9210205A1 *
STN INTERNATIONAL, KARLSRUHE *

Also Published As

Publication number Publication date
KR930703011A (ko) 1993-11-29
AU9149791A (en) 1992-07-08
JPH06503344A (ja) 1994-04-14
WO1992010205A1 (en) 1992-06-25
CA2097825A1 (en) 1992-06-07
EP0560929A1 (en) 1993-09-22

Similar Documents

Publication Publication Date Title
DE4191061T (xx)
DE4190241T (xx)
DE9002331U1 (xx)
DE9003106U1 (xx)
DE9004266U1 (xx)
DE9003486U1 (xx)
DE9000867U1 (xx)
DE9003369U1 (xx)
DE9004653U1 (xx)
DE9003028U1 (xx)
DE9003445U1 (xx)
DE9000803U1 (xx)
DE9004423U1 (xx)
DE9002747U1 (xx)
DE9003003U1 (xx)
DE9001902U1 (xx)
DE9001469U1 (xx)
DE9002624U1 (xx)
DE9001981U1 (xx)
DE9004163U1 (xx)
DE9000176U1 (xx)
DE9001974U1 (xx)
DE9000921U1 (xx)
DE9004172U1 (xx)
DE9001978U1 (xx)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 37/02

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970704

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990701